This systematic review of interferon
treatment in secondary progressive MS (SPMS) includes five randomised
placebo controlled trials of IFNβ in SPMS patients and found that
although relapse rates were reduced in patients receiving treatment vs.
placebo, that disability progression was not.
Authors: La Mantia L, Vacchi L, Rovaris M, Di Pietrantonj C, Ebers G, Fredrikson S, Filippini G.
Source: J Neurol Neurosurg Psychiatry. 2012 Sep 5. [Epub ahead of print]
Read the abstract